• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrinology, Diabetes & Metabolism >Impact on urinary oxalate levels with use of ezetimibe
【24h】

Impact on urinary oxalate levels with use of ezetimibe

机译：利用ezetimibe对尿草酸盐水平的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Calcium oxalate stones are the most common cause of nephrolithiasis in the United States. Smaller studies of 15 patients investigating ezetimibe, a selective cholesterol absorption inhibitor, have suggested increased urine oxalate levels with use of the drug. We attempt to better define this relationship of ezetimibe on urinary oxalate using a larger patient sample analysing multiple urine collections on and off treatment. Materials and Methods We retrospectively reviewed all consecutive patients from 01/2018 through 04/2019 evaluated for nephrolithiasis with use of ezetimibe documented in their medical record at Mayo Clinic Florida. Primary outcomes included increase in urinary oxalate with use of ezetimibe and reduction in urinary oxalate with discontinuation of medication. Results Of 57 reviewed patients, 30 (53%) met inclusion criteria yielding 117 24‐h urine measurements either on ezetimibe (72 measurements) or off ezetimibe (41 measurements). The mean urinary oxalate level off ezetimibe was 39.86?mg versus 40.45?mg with ezetimibe. After adjusting for age and sex, the estimated difference was 1.239?mg (95% CI, ?4.856 to 7.335?mg; p =?0.93). A subset of six patients with urinary oxalate values both on and off ezetimibe showed a difference in 24‐h urinary oxalate levels ranged from ?16.40 to 14.95?mg (mean difference?=?0.93?mg; median difference?=?3.84?mg). Conclusion Use of ezetimibe does not provide clear evidence of a difference in urinary oxalate levels.
机译：背景技术草酸钙石材是美国最常见的肾病成因。较小的研究＆ 15名患者调查ezetimibe是一种选择性胆固醇吸收抑制剂，提出了使用该药物的尿酸盐水平的增加。我们尝试使用较大的患者样品分析多次尿液收集，更好地定义ezetimibe对尿液草酸的这种关系。材料和方法我们回顾性地审查了01/2018至04/2019年04/2019的所有连续患者，在梅奥诊所佛罗里达州的医疗记录中使用ezetimibe评估的肾脏病。主要结果包括使用ezetimibe的尿液酸盐和减少尿草酸尿液，随着药物的停止。结果57名综述患者，30（53％）符合含有117份24-h尿液测量的含量标准（72次测量）或OFF ezetimibe（41测量）。 ezetimibe的平均尿液含量水平为39.86？mg与ezetimibe的40.45毫克。调整年龄和性别后，估计差异为1.239？mg（95％CI，？4.856至7.335？mg; p = 0.93）。患有欧洲纤维菊的六种尿酸盐值的六个患者的子集显示出24-h尿酸盐水平的差异，范围为16.40至14.95？mg（平均差异？=？0.93？mg;中位数差异？=？3.84？MG ）。结论ezetimibe的使用不提供明确的尿液水平差异的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号